Switch theme
Sign up to access all valuation multiples
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
2005
273
LTM Revenue $75.7M
LTM EBITDA -$19.3M
$88.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biodesix has a last 12-month revenue (LTM) of $75.7M and a last 12-month EBITDA of -$19.3M.
In the most recent fiscal year, Biodesix achieved revenue of $71.3M and an EBITDA of -$29.2M.
Biodesix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biodesix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $75.7M | XXX | $71.3M | XXX | XXX | XXX |
| Gross Profit | $59.4M | XXX | $55.8M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | -$19.3M | XXX | -$29.2M | XXX | XXX | XXX |
| EBITDA Margin | -25% | XXX | -41% | XXX | XXX | XXX |
| EBIT | -$32.1M | XXX | -$34.3M | XXX | XXX | XXX |
| EBIT Margin | -42% | XXX | -48% | XXX | XXX | XXX |
| Net Profit | -$40.2M | XXX | -$42.9M | XXX | XXX | XXX |
| Net Margin | -53% | XXX | -60% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $10.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biodesix's stock price is $0.
Biodesix has current market cap of $44.3M, and EV of $88.9M.
See Biodesix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $88.9M | $44.3M | XXX | XXX | XXX | XXX | $-0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biodesix has market cap of $44.3M and EV of $88.9M.
Biodesix's trades at 1.2x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Biodesix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biodesix has a P/E ratio of -1.1x.
See valuation multiples for Biodesix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $44.3M | XXX | $44.3M | XXX | XXX | XXX |
| EV (current) | $88.9M | XXX | $88.9M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | -4.6x | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -2.8x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiodesix's last 12 month revenue growth is 21%
Biodesix's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Biodesix's rule of 40 is -54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biodesix's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biodesix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | -25% | XXX | -41% | XXX | XXX | XXX |
| EBITDA Growth | -54% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -54% | XXX | -20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 126% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biodesix acquired XXX companies to date.
Last acquisition by Biodesix was XXXXXXXX, XXXXX XXXXX XXXXXX . Biodesix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biodesix founded? | Biodesix was founded in 2005. |
| Where is Biodesix headquartered? | Biodesix is headquartered in United States of America. |
| How many employees does Biodesix have? | As of today, Biodesix has 273 employees. |
| Who is the CEO of Biodesix? | Biodesix's CEO is Mr. Scott Hutton. |
| Is Biodesix publicy listed? | Yes, Biodesix is a public company listed on NAS. |
| What is the stock symbol of Biodesix? | Biodesix trades under BDSX ticker. |
| When did Biodesix go public? | Biodesix went public in 2020. |
| Who are competitors of Biodesix? | Similar companies to Biodesix include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Biodesix? | Biodesix's current market cap is $44.3M |
| What is the current revenue of Biodesix? | Biodesix's last 12 months revenue is $75.7M. |
| What is the current revenue growth of Biodesix? | Biodesix revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Biodesix? | Current revenue multiple of Biodesix is 1.2x. |
| Is Biodesix profitable? | Yes, Biodesix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biodesix? | Biodesix's last 12 months EBITDA is -$19.3M. |
| What is Biodesix's EBITDA margin? | Biodesix's last 12 months EBITDA margin is -25%. |
| What is the current EV/EBITDA multiple of Biodesix? | Current EBITDA multiple of Biodesix is -4.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
